Company intelligence / Profile preview

Greengrassbio

Chungju-si, Chungcheongbuk-do, South Korea

Ownership: Private
Development stage: Other

Overview

Greengrassbio has completed multiple clinical research studies on medical foods (Medifood) designed with a specific low Omega-6/Omega-3 ratio. A 4-week randomized crossover clinical trial (NCT04552574) evaluating their Omega-3 Home Meal Replacement (HMR) in obese individuals demonstrated significant reductions in body mass index (BMI), body weight, waist circumference, and systolic blood pressure, as well as a significant decrease in the prevalence of metabolic syndrome.

Therapeutic areas: EndocrinologyOtherMetabolic Disorders
Modalities: Small moleculeNutritional therapy
Industry: Food & Nutrition

Partnerships

Asan Medical CenterMinistry of Agriculture, Food and Rural Affairs (MAFRA)Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET)

Beyond the preview

Go deeper on Greengrassbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greengrassbio.

Explore the full profile